Welcome back. We hope your weekend was pleasant and you feel refreshed. A rainy day here on the Pharmalot corporate campus as the routine returns. And that means meetings and deadlines are looming. To help you along, we have assembled another collection of interesting items. So grab a cup or two of stimulation and dig in. Have a good day, everyone, and stay in touch...
German Report Casts Doubt About Roche's Avastin (Reuters)
Takeda Drugs Tops Rivals In Blood Pressure Studies (Reuters)
Sanofi-Aventis & Glenmark Strike Deal For Pain Drugs (The Wall Street Journal)
Pfizer Sues Ranbaxy Over Rapamune Patent (The Business Standard)
Oslo Court Backs Schering-Plough In Animal Vaccine Dispute (FishNewsEU)
5 Comments
On the Olso Intervet patent win news:
Recall that -- if the current plans of Merck and Sanofi proceed unamended by antitrust, and labour authorities -- these assets will all be contributed to the "New" Merial joint venture, later this year, leaving only 50 percent of any continuing upside for New Merck.
In addition to the merits of the case, I will note my abiding fascination with the idea that each individual salmon must receive an "intraperitoneal injection." How is this feat efficiently accomplished, on what must be hundreds of thousands (if not millions) of live "pharmed" salmon, per year? [One of my commenters linked to an episode of Mike Rowe's "Dirty Jobs" -- to explain it. Cool!]
WHAT!!!!
Salmon
Yes -- your kind are being INJECTED, man!
Heh!
lol
Et tu Ed,
Canon Communications Buys Pharmaceuticals Blog Pharmalot
Los Angeles-based Canon Communications, a publisher and trade show operator serving the pharmaceutical industry, said Monday that it has acquired Pharmalot, a blog focused on news and information in the pharmaceutical industry. Financial terms of the buy were not disclosed. Canon Communications said that Pharmalot founder Ed Silverman joins the firm as part of the buy. Pharmalot becomes part of Canon's Pharmaceutical Media Group. Canon Communications is a unit of Apprise Media LLC.
Salmon